Newbridge Financial Services Group Inc. grew its holdings in shares of Cue Biopharma, Inc. (NASDAQ:CUE – Get Rating) by 41.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,000 shares of the company's stock after buying an additional 5,000 shares during the period. Newbridge Financial Services Group Inc.'s holdings in Cue Biopharma were worth $38,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Engineers Gate Manager LP boosted its stake in Cue Biopharma by 17.7% in the 1st quarter. Engineers Gate Manager LP now owns 25,589 shares of the company's stock worth $125,000 after purchasing an additional 3,849 shares in the last quarter. Amalgamated Bank bought a new position in Cue Biopharma in the 1st quarter worth about $25,000. Swiss National Bank boosted its stake in Cue Biopharma by 8.2% in the 1st quarter. Swiss National Bank now owns 67,600 shares of the company's stock worth $330,000 after purchasing an additional 5,100 shares in the last quarter. Ensign Peak Advisors Inc boosted its stake in Cue Biopharma by 72.7% in the 2nd quarter. Ensign Peak Advisors Inc now owns 17,960 shares of the company's stock worth $45,000 after purchasing an additional 7,560 shares in the last quarter. Finally, Delphia USA Inc. bought a new position in Cue Biopharma during the 2nd quarter valued at about $25,000. Institutional investors own 39.95% of the company's stock.

Analyst Ratings Changes

Several research firms have issued reports on CUE. Piper Sandler began coverage on shares of Cue Biopharma in a research note on Sunday, November 20th. They set an "overweight" rating and a $7.00 target price on the stock. Oppenheimer lowered their target price on shares of Cue Biopharma from $26.00 to $10.00 and set an "outperform" rating on the stock in a research note on Wednesday, August 24th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $15.60.

Cue Biopharma Trading Up 4.7 %

Cue Biopharma (NASDAQ:CUE – Get Rating) last released its quarterly earnings results on Monday, November 14th. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.07. Cue Biopharma had a negative net margin of 500.66% and a negative return on equity of 77.78%. The firm had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.65 million. As a group, analysts predict that Cue Biopharma, Inc. will post -1.43 EPS for the current year.

Cue Biopharma Profile

(Get Rating)

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers.

Read More

• Get a free copy of the StockNews.com research report on Cue Biopharma (CUE)
• Lucid Motors Faces a Reality That May Cloud a Bullish Perception
• Institutions Put Bottom In Rite Aid Shares
• Here's Why You Should Steer Clear of the FedEx Bounce
• Why Did Viking Therapeutics Stock Skyrocket
• NIKE, Inc Swooshes Higher On Results And Outlook

Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.